Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00040950 | Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00005845 | Tipifarnib in Treating Patients With Myelodysplastic Syndromes | completed | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00911066 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia | completed | Phase 1 | 72 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 8 | Pierluigi PorcuOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00985959 | A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) | completed | Phase 1 | 101 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Dec 2, 2013 | clinicaltrials |
| NCT01697020 | Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions | completed | Phase 1 | 70 | Nova Laboratories LimitedINDUSTRY | 1 | Dec 2, 2013 | clinicaltrials |
| NCT00472849 | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias | completed | Phase 1 / Phase 2 | 92 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2013 | clinicaltrials |
| NCT00722488 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma | completed | Phase 1 | 56 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00462787 | Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00096018 | Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 43 | Roswell Park Cancer InstituteOTHER | 1 | Oct 24, 2013 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00003356 | Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | completed | Phase 1 / Phase 2 | 58 | University of RochesterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00258271 | Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 18 | University of RochesterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00016016 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00890500 | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | completed | Phase 1 | 12 | Fate TherapeuticsINDUSTRY | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00079378 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00098423 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301938 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00398515 | Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00470197 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01185262 | Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia(LLC-LENAR-08) | completed | Phase 1 | 25 | MD Anderson International Spain SAOTHER | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00547365 | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | completed | Phase 1 / Phase 2 | 10 | University of TennesseeOTHER | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00405743 | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | completed | Phase 1 / Phase 2 | 153 | Clavis PharmaINDUSTRY | 6 | Sep 18, 2013 | clinicaltrials |
| NCT00807872 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 40 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT01815086 | Radioimmunoimaging of Light Chain (AL) Amyloidosis | completed | Phase 1 | 30 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 70 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 90 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00738829 | Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | completed | Phase 1 / Phase 2 | 45 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00718757 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | completed | Phase 1 | 4 | St. Jude Children's Research HospitalOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00001251 | Phase I Study of Intrathecal Mafosfamide | completed | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2013 | clinicaltrials |
| NCT01212341 | Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor(MG4101) | completed | Phase 1 | 18 | Seoul National University HospitalOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00304018 | Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 5 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT01232712 | A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies | completed | Phase 1 / Phase 2 | 15 | Vaxil Therapeutics Ltd.INDUSTRY | 1 | Aug 9, 2013 | clinicaltrials |
| NCT00003268 | Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | completed | Phase 1 | 39 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00006340 | Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus | completed | Phase 1 | — | Boston Medical CenterOTHER | 4 | Jul 26, 2013 | clinicaltrials |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients(EVOLUTION) | completed | Phase 1 / Phase 2 | 158 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00369226 | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 25, 2013 | clinicaltrials |
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | completed | Phase 1 | 113 | Tesaro, Inc.INDUSTRY | 0 | Jul 25, 2013 | clinicaltrials |
| NCT01161550 | Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML(CLAG ATRA AML) | completed | Phase 1 | 11 | Washington University School of MedicineOTHER | 1 | Jul 23, 2013 | clinicaltrials |
| NCT00002543 | Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors | completed | Phase 1 | 3 | Medical College of WisconsinOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00025129 | VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00049686 | VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00049699 | VNP40101M in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00064090 | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2013source: clinicaltrials